Published in Nature on April 13, 1978
A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc Natl Acad Sci U S A (1984) 5.60
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A (1984) 5.27
Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells. J Virol (1981) 4.38
Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc Natl Acad Sci U S A (1987) 3.98
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Comparison of Epstein-Barr virus strains of different origin by analysis of the viral DNAs. J Virol (1980) 3.00
Epstein-Barr virus DNA XII. A variable region of the Epstein-Barr virus genome is included in the P3HR-1 deletion. J Virol (1982) 2.70
DNA of Epstein-Barr virus. V. Direct repeats of the ends of Epstein-Barr virus DNA. J Virol (1979) 2.63
Simple repeat sequence in Epstein-Barr virus DNA is transcribed in latent and productive infections. J Virol (1982) 2.51
Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells. J Virol (1986) 2.28
The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels. J Virol (1989) 2.13
Repeat array in Epstein-Barr virus DNA is related to cell DNA sequences interspersed on human chromosomes. Proc Natl Acad Sci U S A (1982) 1.81
Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences. J Virol (1981) 1.70
Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci U S A (2003) 1.69
The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J Virol (1992) 1.61
The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J Virol (2002) 1.29
Genomic sequencing and comparative analysis of Epstein-Barr virus genome isolated from primary nasopharyngeal carcinoma biopsy. PLoS One (2012) 1.20
Pleiotropic expression of Epstein--Barr virus DNA in human epithelial cells. Proc Natl Acad Sci U S A (1981) 1.07
New method for large-scale growth; and concentration of the Epstein-Barr viruses. Appl Environ Microbiol (1980) 0.86
A quantitative in vitro focus assay for bovine papilloma virus. Virology (1980) 7.14
Association of cancer with AIDS-related immunosuppression in adults. JAMA (2001) 6.80
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med (1995) 6.77
Spectrum of AIDS-associated malignant disorders. Lancet (1998) 5.30
Cellular origin and role of mink cell focus-forming viruses in murine thymic lymphomas. Nature (1982) 5.23
Molecular cloning of infectious integrated murine leukemia virus DNA from infected mouse cells. Proc Natl Acad Sci U S A (1980) 4.71
Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men. Lancet (1984) 4.68
Origin of mink cytopathic focus-forming (MCF) viruses:comparison with ecotropic and xenotropic murine leukemia virus genomes. Virology (1981) 4.62
Qualitative and quantitative studies of AKR-type murine leukemia virus sequences in mouse DNA. Cold Spring Harb Symp Quant Biol (1975) 4.49
Seroepidemiology of HTLV-III antibody in Danish homosexual men: prevalence, transmission, and disease outcome. Br Med J (Clin Res Ed) (1984) 4.39
Structure of endogenous murine leukemia virus DNA in mouse genomes. Proc Natl Acad Sci U S A (1980) 4.24
Genomes of murine leukemia viruses isolated from wild mice. J Virol (1981) 4.24
Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23
Studies on the transfer of subviral infectivity from SV40-induced hamster tumor cells to indicator cells. Virology (1966) 4.16
Long terminal repeat of murine retroviral DNAs: sequence analysis, host-proviral junctions, and preintegration site. J Virol (1982) 4.06
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med (1989) 4.04
HIV transmission through breastfeeding: a study in Malawi. JAMA (1999) 4.00
Activation of Epstein-Barr virus by 5-bromodeoxyuridine in "virus-free" human cells (complement-fixing antigen-immunofluorescence-leukocytes). Proc Natl Acad Sci U S A (1972) 3.89
Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst (2000) 3.77
Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol (1994) 3.70
Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis (1999) 3.69
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (1991) 3.69
Definitive evidence that the murine C-type virus inducing locus Akv-1 is viral genetic material. Proc Natl Acad Sci U S A (1975) 3.51
Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci (1988) 3.49
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. Science (1986) 3.31
The transforming function of bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1983) 3.19
Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis (1991) 3.16
Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med (1982) 3.08
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med (1999) 3.02
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Evidence that the AKR murine-leukemia-virus genome is complete in DNA of the high-virus AKR mouse and incomplete in the DNA of the "virus-negative" NIH mouse. Proc Natl Acad Sci U S A (1974) 2.95
AKR murine leukemia virus genome: frequency of sequences in DNA of high-, low-, and non-virus-yielding mouse strains. Proc Natl Acad Sci U S A (1974) 2.91
Nucleotide sequence of the 3' end of MCF 247 murine leukemia virus. J Virol (1983) 2.87
Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med (1997) 2.81
Human immunodeficiency virus infection in children. J Pediatr (1989) 2.80
Antibiotic-resistant group JK bacteria in hospitals. J Clin Microbiol (1981) 2.71
High risk of HIV-1 infection for first-born twins. The International Registry of HIV-exposed Twins. Lancet (1991) 2.51
Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J Clin Microbiol (1995) 2.51
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
Appendectomy and subsequent risk of inflammatory bowel diseases. Surgery (2001) 2.35
Trends in HIV incidence among young adults in the United States. JAMA (1998) 2.28
A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med (1986) 2.26
Restriction endonuclease mapping of ecotropic murine leukemia viral DNAs: size and sequence heterogeneity of the long terminal repeat. Virology (1981) 2.25
The AIDS problem in Africa. Lancet (1986) 2.25
Detection of Candida antigen in sera of patients with candidiasis by an enzyme-linked immunosorbent assay-inhibition technique. J Clin Microbiol (1979) 2.13
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother (1995) 2.12
Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 2.11
Factors associated with disclosure of diagnosis to children with HIV/AIDS. Pediatr AIDS HIV Infect (1996) 2.09
Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome. J Pediatr (1990) 2.07
Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study. Ann Intern Med (1986) 2.06
Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis (1994) 2.04
Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial. BMJ (1997) 2.03
Solid tumors after chronic lymphocytic leukemia. Blood (2001) 2.01
Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS (1992) 1.97
Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis (1988) 1.95
Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 1.95
Variation in human T lymphotropic virus III (HTLV-III) antibodies in homosexual men: decline before onset of illness related to acquired immune deficiency syndrome (AIDS). Br Med J (Clin Res Ed) (1985) 1.93
To resuscitate or not, that is the question. Med J Aust (1989) 1.93
Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. Annu Rev Microbiol (1988) 1.92
Induction of cellular DNA synthesis in human leukocytes by Epstein-Barr virus. Nature (1971) 1.91
Complement-fixing antibodies in sera of human and nonhuman primates to viral antigens derived from Burkitt's lymphoma cells. Proc Natl Acad Sci U S A (1967) 1.91
Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med (1988) 1.91
Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst (1991) 1.91
Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med (1988) 1.90
Epstein-Barr virus RNA in Burkitt tumor tissue. Cell (1979) 1.88
Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr (1995) 1.86
ELISA HTLV retrovirus antibody reactivity associated with malaria and immune complexes in healthy Africans. Lancet (1985) 1.85
Selective transformation of B lymphocytes by E.B. virus. Lancet (1973) 1.84
Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and granulocytopenia. Am J Med (1982) 1.84
Binding and suppression of the Myc transcriptional activation domain by p107. Science (1994) 1.84
Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer (1997) 1.82
Sexual transmission of hepatitis C virus: cohort study (1981-9) among European homosexual men. BMJ (1990) 1.81
Studies on leukocytes growing in continuous culture derived from normal human donors. J Natl Cancer Inst (1968) 1.80
Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood (1994) 1.79
Interassay correlation of human herpesvirus 8 serologic tests. HHV-8 Interlaboratory Collaborative Group. J Infect Dis (1998) 1.79
Factors that could influence the spread of AIDS in Ghana, West Africa: knowledge of AIDS, sexual behavior, prostitution, and traditional medical practices. J Acquir Immune Defic Syndr (1991) 1.77
Interactions between persons at risk for AIDS and the general population in Denmark. Am J Epidemiol (1992) 1.76
B-cell characteristics of human peripheral and cord blood lymphocytes transformed by Epstein-Barr virus. J Natl Cancer Inst (1974) 1.75
Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood (1997) 1.73
Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood (1991) 1.73
Oral excretion of Epstein-Barr virus by healthy subjects and patients with infectious mononucleosis. Lancet (1972) 1.71
How far should we investigate and treat prostate cancer? A lawyer's perspective. Med J Aust (1994) 1.71
Preventing AIDS now. BMJ (1991) 1.71
Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis (1991) 1.70
Cancer in children with primary or secondary immunodeficiencies. J Pediatr (1995) 1.70
Comparison of lysis-centrifugation with lysis-filtration and a conventional unvented bottle for blood cultures. J Clin Microbiol (1984) 1.67
Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J (1996) 1.66
Combined histologic and molecular features reveal previously unappreciated subsets of lymphoma in AKXD recombinant inbred mice. Leuk Res (2001) 1.64
Induced sputum to diagnose Pneumocystis carinii pneumonia in immunosuppressed pediatric patients. J Pediatr (1989) 1.63
High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group. Lancet (1994) 1.62
CD4+ subset regulation in viral infection. Preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice. J Immunol (1992) 1.62
Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother (1994) 1.61
Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med (1979) 1.61
Stimulatory effect of counterflow centrifugal elutriation in large-scale separation of peripheral blood monocytes can be reversed by storing the cells at 37 degrees C. J Clin Apher (1991) 1.61
Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. JAMA (1987) 1.60